Paper9605801
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998. Cited by 3,176 papers, by iCite.
Cite this record
ConductScience Library. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Papers, record 9605801. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9605801
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Hormonal | Major topic |
| Breast Neoplasms | Major topic |
| Tamoxifen | Major topic |
| Adult | |
| Age Factors | |
| Aged | |
| Carrier Proteins | |
| Chemotherapy, Adjuvant | |
| Colorectal Neoplasms | |
| Endometrial Neoplasms | |
| Female | |
| Humans | |
| Incidence | |
| Menopause | |
| Middle Aged | |
| Neoplasm Recurrence, Local | |
| Receptors, Estrogen | |
| Survival Rate | |
| Time Factors |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00603967 | Effect of Aromatase Inhibitors on Bones and Genes | Background | ClinicalTrials.gov | |
| NCT03917082 | Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer | Background | ClinicalTrials.gov |
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 9717952 | Tamoxifen in early breast cancer. | https://conductscience.org/library/papers/9717952 | PubMed |
| Comment in | 9717953 | Tamoxifen in early breast cancer. | https://conductscience.org/library/papers/9717953 | PubMed |
| Comment in | 9717954 | Tamoxifen in early breast cancer. | https://conductscience.org/library/papers/9717954 | PubMed |
| Comment in | 9717955 | Tamoxifen in early breast cancer. | https://conductscience.org/library/papers/9717955 | PubMed |
Cited by867
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,176 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42980869 | Co-payments and adherence to endocrine therapy among Medicaid beneficiaries with breast cancer. | Breast Cancer Res Treat | 2026 | https://conductscience.org/library/papers/42980869 | PubMed |
| 42959345 | Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42959345 | PubMed |
| 42844328 | ESR1 mutations are associated with enhanced MTORC1 signaling in a context-dependent manner. | Commun Biol | 2026 | https://conductscience.org/library/papers/42844328 | PubMed |
| 42804883 | Performance of large language models in ambiguous treatment scenarios of early breast cancer. | Breast | 2026 | https://conductscience.org/library/papers/42804883 | PubMed |
| 42584460 | Tamoxifen Therapy Is Associated With Altered Intestinal P-Glycoprotein Activity In Vivo. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42584460 | PubMed |
| 42350394 | Prognostic consistency of oncotype DX® molecular assay across racial groups in early-stage hormone receptor-positive breast cancer. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/42350394 | PubMed |
| 42123574 | MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics-Potential to Advance Personalised Approaches in Clinical Trials. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123574 | PubMed |
| 41939469 | Tamoxifen differentially modulates endometrial hyperplasia via wild-type and mutant p53 regulation of the ALKBH5-REG1A axis. | Front Oncol | 2026 | https://conductscience.org/library/papers/41939469 | PubMed |
| 41821351 | Recurrence Rate Following Breast Conservation Surgery: A Retrospective Cohort Study. | Breast J | 2026 | https://conductscience.org/library/papers/41821351 | PubMed |
| 41634433 | Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/41634433 | PubMed |
| 41483282 | Interplay between AIB1 genotypes and radiotherapy in a Swedish population-based breast cancer cohort. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41483282 | PubMed |
| 41474498 | Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41474498 | PubMed |
| 41469392 | Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer. | NPJ Breast Cancer | 2025 | https://conductscience.org/library/papers/41469392 | PubMed |
| 41005350 | Racial Differences in Symptom Burden and Endocrine Therapy Adherence in Breast Cancer: A Post Hoc Analysis of a Randomized Trial. | J Natl Compr Canc Netw | 2025 | https://conductscience.org/library/papers/41005350 | PubMed |
| 40906937 | Cholesterol-Functionalized Porous PLA Microparticles for Enhanced Drug Delivery. | ACS Appl Bio Mater | 2025 | https://conductscience.org/library/papers/40906937 | PubMed |
| 40746386 | Leveraging values to promote adherence to endocrine therapy among breast cancer survivors: A mixed-methods investigation. | J Contextual Behav Sci | 2022 | https://conductscience.org/library/papers/40746386 | PubMed |
| 40600576 | CYP2D6 genotype and outcome in tamoxifen treated early breast cancer. | Acta Oncol | 2025 | https://conductscience.org/library/papers/40600576 | PubMed |
| 40571497 | Medicines and society: systemic change needed to address overprescribing. | Br J Gen Pract | 2025 | https://conductscience.org/library/papers/40571497 | PubMed |
| 40557948 | How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy? | Acta Oncol | 2025 | https://conductscience.org/library/papers/40557948 | PubMed |
| 40490470 | Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention. | NPJ Breast Cancer | 2025 | https://conductscience.org/library/papers/40490470 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Authors
- Grants
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9605801
GET https://conductscience.org/api/papers/v1/9605801/cited_by?page=2